Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB06674
http://purl.obolibrary.org/obo/dinto_DB06674
|
|---|---|
| Preferred Name | golimumab |
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | golimumab
|
|---|---|
| label | golimumab
|
| DBSynonym | cnto 148
|
| ATCCode | L04AB06
|
| Definition | Golimumab is a human IgG1? monoclonal antibody derived from immunizing genetically engineered mice with human TNF?. Golimumab binds and inhibits soluble and transmembrane human TNF?. Increased TNF? is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi?. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
|
| has pharmacological target | |
| type | |
| xref |
Drugs.com:http://www.drugs.com/mtm/golimumab.html
Wikipedia:http://en.wikipedia.org/wiki/Golimumab
RxList:http://www.rxlist.com/simponi-drug.htm
National Drug Code Directory:57894-071-01
|
| CASRN | 476181-74-5
|
| prefixIRI | obo2:dinto_DB06674
|
| related with | |
| may interact with |
See more
See less
|
| DBBrand | simponi?
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |